secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001104659-25-029401
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia's YUTREPIA NDA resubmission accepted; PDUFA date May 24, 2025
----------------------------------------------------------------------

- FDA accepted Liquidia's NDA resubmission for YUTREPIA (treprostinil) inhalation powder.
- Resubmission is a complete, Class 1 response to the August 16, 2024 action letter.
- FDA granted tentative approval for PAH and PH-ILD; final approval decision by May 24, 2025.
- Company preparing for launch of YUTREPIA pending final FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/0001104659-25-029401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/tm2510788-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer